Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, dr_lowenstein, NASDAQ2020, IB_, namtae, Chasing
Search This Board: 
Last Post: 2/20/2018 10:56:07 AM - Followers: 833 - Board type: Free - Posts Today: 22

Elite Pharmaceuticals, Inc. (ELTP)

About Elite Pharmaceuticals
Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology. 
Located in Northvale, New Jersey, Elite operates a 55,000 square foot campus under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development, manufacturing and packaging of pharmaceutical products.
More information including Elite’s proprietary Abuse Resistant Technology can be found at

About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the Company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
Elite continues to expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.
Products & Pipeline
Elite’s principle product is SequestOx, an immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain. Additional products include bariatric, cardiovascular, antihistamine, skeletal muscle relaxants, antipsychotic, tricyclic antidepressant, along with a number of approved products pending manufacturing site transfer.
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Additional information regarding Elite’s wholly owned products, partnerships, and contract manufacturing can be found at
The list of pipeline products can be found at
Nasrat Hakim, Chairman, President & Chief Executive Officer
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership.  Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company. 

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters
165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755


Miscellaneous Links:
Elite Pharmaceuticals News
SEC Filings

FDA website

Clinical Trials.Gov
Yahoo Finance
Seeking Alpha

ELTP Daily Chart

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP News: Current Report Filing (8-k) 02/09/2018 05:03:16 PM
ELTP News: Quarterly Report (10-q) 02/09/2018 04:44:24 PM
ELTP News: Current Report Filing (8-k) 02/08/2018 01:39:57 PM
ELTP News: Current Report Filing (8-k) 01/31/2018 07:38:14 AM
ELTP News: Current Report Filing (8-k) 01/10/2018 04:46:51 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#283248  Sticky Note ELTP Conference Call Information this Friday, February 12 conix 02/08/18 03:51:55 PM
#279326  Sticky Note The last close out letter from the FDA toofun 12/08/17 11:57:54 AM
#274770  Sticky Note memorable "calls" for elite pharma: dr_lowenstein 10/24/17 04:09:11 PM
#271038  Sticky Note Elite Pharma at Pain Week 2017 NASDAQ2020 09/17/17 04:03:01 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#185967  Sticky Note The only topic here is ELTP. IH Dan (Retired) 02/23/16 09:32:46 PM
#284247   You can call as many BS as you Investintin 02/20/18 10:56:07 AM
#284246   I am expecting another CRL, what are you stockboy 02/20/18 10:00:07 AM
#284245   WeeZuhl, could you comment on Eaglet's AD formulation? senderos 02/20/18 09:55:50 AM
#284244   if this technology works, the preliminary results would WeeZuhl 02/20/18 09:44:58 AM
#284243   Which one do you expect first? TIA NASDAQ2020 02/20/18 09:43:03 AM
#284242   Maybe 2020 more like it! stockboy 02/20/18 09:37:15 AM
#284241   Eltp dropping again where’s that news again? stockboy 02/20/18 09:36:42 AM
#284240   The inside opposition of ADFs by the FDA, namtae 02/20/18 09:32:43 AM
#284239   Im ready, whether its this week or next. NASDAQ2020 02/20/18 09:32:02 AM
#284238   Agreed, and I am also of the opinion Gman24 02/20/18 09:25:34 AM
#284237   Where is that BIG PR today? ??’s. stockboy 02/20/18 09:22:38 AM
#284236   While you are correct in that the tech toofun 02/20/18 09:17:13 AM
#284235   probably when Elite shows positive results on their Investintin 02/20/18 09:04:27 AM
#284234   At some point, probably when Elite shows positive toofun 02/20/18 08:34:59 AM
#284233   We will see .50 long before this ridiculous Gman24 02/20/18 08:15:55 AM
#284232   Someone said $.50 is a steal, BUT it’s stockboy 02/20/18 08:06:57 AM
#284231   Elites 2 bead tech creating more CRL’s more stockboy 02/20/18 07:56:45 AM
#284230   Elites 2 bead ADFs are creating a NEW NASDAQ2020 02/20/18 07:50:51 AM
#284229   More like 1 Billion share float with zero stockboy 02/20/18 07:44:23 AM
#284228   $$$$Elite's Multi-Billion Dollar PipeLine: $$$$ NASDAQ2020 02/20/18 07:39:54 AM
#284227   Yes hiding anything detrimental tonUN-Elite is NasRAT’s forte. stockboy 02/20/18 06:08:09 AM
#284226   Just give it time and more dilution, more stockboy 02/20/18 06:03:30 AM
#284225   :Cramer said he was trying to develop a greenlife 02/19/18 11:07:10 PM
#284224   From an article by Cramer about Teva pharma greenlife 02/19/18 11:04:08 PM
#284223   Agree that part of this has been that Jimmy Joe 02/19/18 10:46:09 PM
#284222   Per Nasrat, the initial PIII was a success jour_trader 02/19/18 09:14:46 PM
#284221   Those low-lifes over at Pfizer STILL haven't launched Troxyca. aELmTPa 02/19/18 08:58:26 PM
#284220   "According to the current share price that is inaccurate." IB_ 02/19/18 07:14:23 PM
#284219   Ok I now see the light. Eltp is dr_lowenstein 02/19/18 06:20:27 PM
#284217   If this 2 bead tech is so good stockboy 02/19/18 05:33:51 PM
#284216   LOL how can they be in the running stockboy 02/19/18 05:27:28 PM
#284215   I guess that leaves out UN-elite. stockboy 02/19/18 05:26:18 PM
#284214   Oh so looks there won't be a PR stockboy 02/19/18 05:24:00 PM
#284213   Big Pharma could buy UN-elite for peanuts. Then stockboy 02/19/18 05:22:29 PM
#284212   A buyout doesn't have to come. NasRAT first stockboy 02/19/18 05:21:43 PM
#284210   So far, what we know for sure is namtae 02/19/18 02:41:48 PM
#284209   Elite's 2 bead ER and IR ADF opiods NASDAQ2020 02/19/18 02:33:01 PM
#284208   FDA pushing for that FIRST EVER AD NASDAQ2020 02/19/18 02:29:51 PM
#284207   The self dealing CEO should have filed his namtae 02/19/18 01:40:59 PM
#284206   I have to think based upon a conference snupoled 02/19/18 01:27:07 PM
#284205   Same old broken record about Sequest and the namtae 02/19/18 01:23:32 PM
#284204   the powerful groups that are keeping ADFs off Investintin 02/19/18 01:14:21 PM
#284203   Right on JJ I’m on board with your bro rocioyogi 02/19/18 01:03:01 PM
#284201   Rocioyogi, even if Ama's dream comes true with Jimmy Joe 02/19/18 12:47:36 PM
#284200   As I said in my post -Tuesday or rocioyogi 02/19/18 12:41:09 PM
#284199   $10 million is a drop in a 5 Jimmy Joe 02/19/18 12:36:52 PM
#284197   Ever thought about "WHY" Elite has not been IB_ 02/19/18 12:27:24 PM
#284196   NASDAQ LMAO! I averaged UP too. Anything below Jimmy Joe 02/19/18 12:23:31 PM
#284195   Questions, Questions, Questions... no2koolaid 02/19/18 12:21:44 PM
#284194   The Esquire article has shown another problem that Jimmy Joe 02/19/18 12:19:56 PM